Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kaken’s Axillary Hyperhidrosis Treatment Hits Primary Goal in Japan PIII Study
June 16, 2020
- 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Takeda, Mitsubishi-UBS Asset JV to Collaborate in Shonan iPark Operations
June 15, 2020
- PeptiDream, US Merck Link Up to Develop COVID-19 Treatment
June 15, 2020
- Daiichi Sankyo to Kickstart COVID-19 Vaccine Development
June 15, 2020
- AbbVie Files Rinvoq for Psoriatic Arthritis in Japan
June 15, 2020
- Takeda to Divest 18 Non-Core Meds in Asia-Pacific to Celltrion for US$278 Million
June 12, 2020
- Ono/Seikagaku’s Novel Osteoarthritis Drug Delivers in Japan PIII for Knee Pain
June 12, 2020
- 100 mg Version of Vimpat IV Infusion Now Available in Japan: UCB
June 12, 2020
- Shonan iPark to Launch VC Consortium
June 12, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- Sanofi Rolls Out Soliqua Injection SoloStar for Type 2 Diabetes in Japan
June 10, 2020
- Xofluza Shows Favorable Results in Patients at High Risk of Flu Complications in Global PIII: Shionogi
June 10, 2020
- Japan Ethical Drug Sales Up 2.6% in April: Crecon
June 10, 2020
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
- Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
June 9, 2020
- Evrenzo Shows Non-Inferiority to Nesp in Non-Dialysis CKD Patients
June 9, 2020
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…